 |
|
Still not a subscriber to JACC Imaging or JACC Interventions?
|
|
ACC.07 and i2 Summit Highlights: A Conversation With the Experts
E. Murat Tuzcu, MD, FACC, Chair,
Randall C. Starling, MD, MPH, FACC, Co-Chair and
James D. Thomas, MD, FACC, Co-Chair
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Assessment of Antianginal Effects in the MERLIN-TIMI 36 Trial
Selected efficacy end points in the MERLIN-TIMI 36 trial. Based on Kaplan-Meier cumulative incidence (%) at 12 months. Primary end point: cardiovascular (CV) death/myocardial infarction (MI)/recurrent ischemia (RI). *p = 0.11;  p = 0.03;  p = 0.023. Blue bars = ranolazine (n = 3,279); yellow bars = placebo (n = 3,281).
|
|
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Trend for DBT for 586 National Cardiovascular Data Registry Hospitals
Data are based on the hospital’s ability to perform percutaneous coronary intervention (PCI) in their composite patients in <90 min. DBT = door-to-balloon time.
|
|
View larger version (45K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Definite ST and MI After Implantation of DES or BMS in Western Denmark
(A) Definite stent thrombosis (ST) and (B) myocardial infarction (MI). BMS = bare-metal stent(s); DES = drug-eluting stent(s); RR = risk ratio.
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 MACE and TLR Through 270 (± 14) Days in the SPIRIT III Trial
Blue bars = XIENCE V (n = 658); yellow bars = TAXUS (n = 322). ID = ischemia-driven; MACE = major adverse cardiac events; NID = nonischemia-driven; TLR = target lesion revascularization.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 11 Kaplan-Meier Analyses of All-Cause Mortality and Cardiovascular Mortality or Hospitalization for Heart Failure in the EVEREST Trial
Reprinted with permission from Konstam et al. (61).
|
|
View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 13 Predictive Value of Dyssynchrony Patterns
Dyssynchrony was assessed in 2 planes: longitudinal (tissue Doppler imaging) and radial (speckle tracking radial strain). Response was defined as end-systolic volume (ESV) decrease  10% or ejection fraction (EF) increase 15%. Of 173 patients, 119 (69%) were EF responders. Light blue bars = ESV responders; dark blue bars = EF responders. *p < 0.05 versus both; #p < 0.05 versus either.
|
|
View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 14 Survival Curves for Rate Versus Rhythm Control in Patients With AF and Diastolic Heart Failure
Using a 60-day landmark view to assess medication usage, Kaplan-Meier curves for rate versus rhythm control were adjusted for baseline patient differences using Cox proportional hazards modeling. AF = atrial fibrillation.
|
|
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 16 Survival Free of Cardiac Death in Patients Without Recent Angiography
Chi-square = 4.5; hazard ratio = 0.4; 95% confidence interval = 0.17 to 0.96; p = 0.035. PET = positron emission tomography.
|
|
|
|
